Indexed with PubMed and Science Citation Index (E) 
Users online: 1175 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
    Next article
    Previous article
    Table of Contents

    Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded1    
    Comments [Add]    

Recommend this journal


Year : 1996  |  Volume : 62  |  Issue : 4  |  Page : 231--232

Mesalazine in treatment of psoriasis

Sri Guru Ram Das and Civil Hosptials, Amritsar, India

Correspondence Address:
Rakesh Bharti
424-Basant Avenue, Amritsar
Login to access the Email id

Source of Support: None, Conflict of Interest: None

PMID: 20948062

Rights and PermissionsRights and Permissions

Mesalazine- a 5 lipoxygenase inhibitor was tried in this open trial on 20 psoriatics. Whereas 50% patients (10) had complete clearance in 4 weeks, by 12 weeks 85% (17) patients had good response and 15% (3) patients had no relief at all. No side effects were observed.Further longitudinal double-blind trials of this drug, which has an advantage of not causing bone marrow depression and oligospermia over sulfasalazine, another 5 lipoxygenase inhibitor, are advocated.


Print this article     Email this article

Online since 15th March '04
Published by Wolters Kluwer - Medknow